Abstract:IMPORTANCE: Whole-genome sequencing (WGS) is increasingly applied in clinical medicine and is expected to uncover clinically significant findings regardless of sequencing indication.OBJECTIVES: To examine coverage and concordance of clinically relevant genetic variation provided by WGS technologies; to quantitate inherited disease risk and pharmacogenomic findings in WGS data and resources required for their discovery and interpretation; and to evaluate clinical action prompted by WGS findings.DESIGN, SETTING, AND PARTICIPANTS: An exploratory study of 12 adult participants recruited at Stanford University Medical Center who underwent WGS between November 2011 and March 2012. A multidisciplinary team reviewed all potentially reportable genetic findings. Five physicians proposed initial clinical follow-up based on the genetic findings.MAIN OUTCOMES AND MEASURES: Genome coverage and sequencing platform concordance in different categories of genetic disease risk, person-hours spent curating candidate disease-risk variants, interpretation agreement between trained curators and disease genetics databases, burden of inherited disease risk and pharmacogenomic findings, and burden and interrater agreement of proposed clinical follow-up.RESULTS: Depending on sequencing platform, 10% to 19% of inherited disease genes were not covered to accepted standards for single nucleotide variant discovery. Genotype concordance was high for previously described single nucleotide genetic variants (99%-100%) but low for small insertion/deletion variants (53%-59%). Curation of 90 to 127 genetic variants in each participant required a median of 54 minutes (range, 5-223 minutes) per genetic variant, resulted in moderate classification agreement between professionals (Gross κ, 0.52; 95% CI, 0.40-0.64), and reclassified 69% of genetic variants cataloged as disease causing in mutation databases to variants of uncertain or lesser significance. Two to 6 personal disease-risk findings were discovered in each participant, including 1 frameshift deletion in the BRCA1 gene implicated in hereditary breast and ovarian cancer. Physician review of sequencing findings prompted consideration of a median of 1 to 3 initial diagnostic tests and referrals per participant, with fair interrater agreement about the suitability of WGS findings for clinical follow-up (Fleiss κ, 0.24; P < 001).CONCLUSIONS AND RELEVANCE: In this exploratory study of 12 volunteer adults, the use of WGS was associated with incomplete coverage of inherited disease genes, low reproducibility of detection of genetic variation with the highest potential clinical effects, and uncertainty about clinically reportable findings. In certain cases, WGS will identify clinically actionable genetic variants warranting early medical intervention. These issues should be considered when determining the role of WGS in clinical medicine.

Population scale whole genome sequencing provides novel insights into cardiometabolic health

Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank

WHOLE GENOME SEQUENCING ANALYSIS OF BODY MASS INDEX IDENTIFIES NOVEL AFRICAN ANCESTRY-SPECIFIC RISK ALLELE

Whole exome sequencing and characterization of coding variation in 49,960 individuals in the UK Biobank

An Atlas of Genetic Influences on Human Blood Metabolites

Exome sequencing and analysis of 454,787 UK Biobank participants

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Whole-Genome Sequencing Coupled to Imputation Discovers Genetic Signals for Anthropometric Traits.

Whole-genome sequencing in 333,100 individuals reveals rare non-coding single variant and aggregate associations with height

Genetic associations of protein-coding variants in human disease

Yield of genetic association signals from genomes, exomes and imputation in the UK Biobank

Whole-Genome Sequencing Analysis of Human Metabolome in Multi-Ethnic Populations

Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes

Identifying novel genetic and phenotypic associations to genomic features by leveraging off-target reads in exome sequencing data

Genetic ancestral patterns in alleles: structural variants, rare variants, and clinical associations in 479,144 UK Biobank genomes

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medications

Whole genome association testing in 333,100 individuals across three biobanks identifies rare non-coding single variant and genomic aggregate associations with height

Clinical Interpretation and Implications of Whole-Genome Sequencing

Integrating Genetic and Transcriptomic Data to Identify Genes Underlying Obesity Risk Loci

Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity

A coding and non-coding transcriptomic perspective on the genomics of human metabolic disease